Fig. 1: Design of LVs optimized for poly-neoepitope presentation. | npj Vaccines

Fig. 1: Design of LVs optimized for poly-neoepitope presentation.

From: Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity

Fig. 1: Design of LVs optimized for poly-neoepitope presentation.

a Schematic representation of the transcriptional unit used for LV vector RNA production: U3RU5: 5’ Long Terminal Repeat; φ: encapsidation signal; RRE: Rev Response Element; cPPT/CTS: central PolyPurine Tract / Central Termination Sequence; β2m: Beta-2-microglobulin promoter; Wm: Woodchuck Post-transcriptional Regulatory Element with the internal HBx protein ORF mutation, M1A. b Schematic representation of optimization neoepitope design to enhance presentation through the MHC-I endogenous pathway. Selected CD8+ MC38-specific neoepitope sequences are shown in gray boxes, with mutated residues highlighted in red, spacer sequences in brown and proteasome addressing sequences in blue/red boxes. UbC G76V: Mouse ubiquitin C with a mutation of cleavage site G76V (Uniprot: P0CG50 - aa 1-76). PEST: PEST sequence from mouse Ornithine Decarboxylase (Uniprot: P00860 - aa 422-461).

Back to article page